MEDICAL DEVICES VENTURE: First-half 2023 results – 08/01/2023 at 08:15

Igny, 1

^er

August 2023– Medical Devices Venture, an investment platform for start-ups developing healthcare solutions, announces its results for the first half of 2023.

Medical Devices Venture invests in start-ups whose objective is to improve prevention, monitoring and the patient’s medical journey at home.

Drawing on the recognized expertise in research and development, operational and logistical support, marketing and sales and industrial know-how of the ARCHOS group, Medical Devices Venture brings a set of key skills for the launch of new products.

Activity and highlights of the semester

Turnover and activity of subsidiaries

The Group records revenue of €10,000 in the first half of 2023.

The activity of the subsidiaries of Medical Devices Venture over the half-year is as follows:

DEXTRAIN SAS

Dextrain specializes in the development and marketing of innovative medical devices and digital solutions for the assessment and rehabilitation of manual dexterity.

Following the obtaining of funding from the National Research Agency, the development of the Dextrain-Haptics project in collaboration with the INSERM u1266 laboratory has begun. This funding will cover clinical trials that will establish the value of this new approach for recovering tactile sensitivity in patients who have suffered a stroke. These studies will also make it possible to evaluate the impact of an affected tactile sensitivity on the chances of recovery of dexterity after a stroke.

During the first semester DEXTRAIN deployed new exercises for the Dextrain Manipulandum to allow a more complete, more targeted and more motivating rehabilitation for patients.

Finally, the company continued to develop a new version of Dextrain Manipulandum intended for daily use by the patient at home. As hospitalization times are limited, many stroke patients go home with untreated dexterity deficits. To date, there is no affordable tool that can be used from home to continue hand rehabilitation. This new tool will be presented by Dextrain during the 2

^th

semester 2023.

On the commercial level, the test phases are continuing in more than ten rehabilitation centers or hospitals.

Poladerm SAS

Poladerme is developing a connected dermascope that can take spectropolarimetric photos to restore images invisible to the naked eye of the skin and its components.

The hardware solution is finalized and the tooling will be launched, the first production parts should be available during the 2

^th

semester.

The software development started with the porting of the versions used in the research laboratories to a version that could be accessible to a wider public of health professionals. The team should be able to start carrying out the first tests of taking photos and analyzing certain biomarkers such as collagen, in real conditions, on the 2

^th

semester 2023.

POLADERME was the winner in June 2023 of a prize awarded by the Force Foundation, a mark of recognition of the relevance of the research work carried out by the team.

MDV IT SAS

Orders have already been confirmed for an amount of 630 Keuros in the first half of the year and they will be delivered and invoiced in the second half of 2023.

LIFI MED SAS

The company has had no activity since its creation. The Lifi market is still in the making despite developments in the standardization of protocols. The Group is studying development opportunities but remains cautious about the investments to be made.

DOMISANTE SAS

The challenge for DOMISANTE is to embody, in a health gateway, a complete solution, a sort of one-stop shop, so that the patient can be an actor in his health at home.

The deployment of the DOMISANTE solution is carried out in partnership with health and home care players. This solution presented at the SANTEXPO trade fair in May 2023 has met with great success with healthcare and home care players (SSIAD, HAD, Maison Partagée, personal assistance).

It will be deployed in tests in different environments (home nursing care, shared homes, hospitalization at home) from the second half of the year.

SYNTHETIC INCOME STATEMENT

The other products correspond to French Tech Emergence Grants (Poladerme and Dextrain).

Operating expenses are up by 21%.

Operating income stood at -€362K compared to -€375K in the first half of 2022.

Exceptional income amounted to +€90,000 and is made up of Dextrain’s 2022 CIR for €90,000 (recognized after the 2022 closing and therefore classified as exceptional income at June 30, 2023).

Consolidated net income stands at -€277K for the first half of 2023 compared to -€287K for the first half of 2022.

MAIN CONSOLIDATED BALANCE SHEET ITEMS

Net cash

Net cash stood at €1,672,000, down €161,000 over the half-year. The change in cash results from the negative CAF.

Outlook

:

MEDICAL DEVICES VENTURE intends to invest in new innovative projects in 2023.

MEDICAL DEVICES VENTURES, an impact company, wishes to position itself as the operational and industrial bridge of French academic research in the coming years.

About Medical Devices Venture

A subsidiary of ARCHOS, Medical Devices Venture, is a holding company that develops a portfolio of investments in Med Tech start-ups. The objective is to combine the expertise of researchers in hospitals and universities with the industrialization, certification and marketing strength of the group. Medical Devices Venture is listed on the Euronext Access + Paris market. ISIN: FR0014006PT9 – mnemo: MLMDV

More information: www.medicaldevicesventure.com

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com